Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zai Lab Ltd ADR (NQ: ZLAB )

27.50 +0.21 (+0.77%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Zai Lab Ltd ADR

< Previous 1 2 3 Next >
Zai Lab Limited (NASDAQ:ZLAB) Investor Alert: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 11/15/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Zai Lab Limited. 
Via SBWire
Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Announces Participation in November Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023
- Company to Host Conference Call and Webcast on November 8, 2023, at 8:00 a.m. ET 
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Limited (NASDAQ:ZLAB) Investor Notice: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 07/31/2023 -- Zai Lab Limited is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China
Candidate precision medicine has shown encouraging clinical activity for both ROS1-positive NSCLC and NTRK fusion-positive advanced solid tumors 
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Announces Participation in September Investor Conferences
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates
From Zai Lab Limited
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Zai Lab, Bowlero, and Chegg and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Zai Lab to Announce Second Quarter 2023 Financial Results and Corporate Updates on August 7, 2023
- Company to Host Conference Call and Webcast on August 8, 2023, at 8:00 a.m. ET 
From Zai Lab Limited
Via GlobeNewswire
JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients
From Zai Lab Limited
Via GlobeNewswire
Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
From Zai Lab Limited
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Zai Lab Announces First Patient Treated in Mainland China for the Global Phase 3 FORTITUDE-101 Study of Bemarituzumab in First-Line Gastric Cancer
From Zai Lab Limited
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod Alfa Injection (Subcutaneous Injection) for Patients with Generalized Myasthenia Gravis
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Announces Promotion of Yajing Chen to Chief Financial Officer
From Zai Lab Limited
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Zai Lab Limited Investors to Inquire About Securities Class Action Investigation - ZLAB
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Zai Lab Limited Investors to Inquire About Securities Class Action Investigation - ZLAB
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ROSEN, A LEADING LAW FIRM, Encourages Zai Lab Limited Investors to Inquire About Securities Class Action Investigation - ZLAB
WHY: New York, NY - (NewMediaWire) - July 02, 2023 - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zai Lab... 
Via NewMediaWire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Hayward and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
From Zai Lab Limited
Via GlobeNewswire
Zai Lab Announces NDA Acceptance of Repotrectinib for Patients with ROS1-positive NSCLC by China’s NMPA
From Zai Lab Limited
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Zai Lab, Hayward, Ascendis, and Alvotech and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ZLAB LOSS ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Zai Lab Limited Investors to Inquire About Securities Class Action Investigation - ZLAB
WHY: New York, NY - (NewMediaWire) - June 23, 2023 - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zai Lab... 
Via NewMediaWire
ZAI LAB ALERT: Bragar Eagel & Squire, P.C. is Investigating Zai Lab Limited on Behalf of Zai Lab Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.